Towerview LLC boosted its holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) by 27.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 436,873 shares of the company’s stock after purchasing an additional 94,395 shares during the period. Corvus Pharmaceuticals accounts for approximately 0.5% of Towerview LLC’s portfolio, making the stock its 17th […]
Corvus Pharmaceuticals, Inc. announced the initiation of the Company?s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) – Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) per share for the year, up from their prior estimate of […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,490,000 shares, an increase of 17.3% from the February 29th total of 1,270,000 shares. Based on an average daily trading volume, of 218,100 […]